Rajiv Malik

Biography

Rajiv Malik is president of Mylan and also serves on the company’s board of directors. He leads all global commercial and operational activities for the company, including sales and marketing in more than 165 countries and territories and operations that manage a portfolio of more than 7,500 marketed products, a pipeline of approximately 1,200 products and 50 manufacturing facilities around the world. Mylan has a manufacturing capacity of more than 80 billion doses annually with capabilities that include oral solid doses, injectables, complex products including respiratory and biologics, and active pharmaceutical ingredients (API). The functions managing these diverse capabilities include quality, R&D, regulatory, medical affairs, manufacturing, supply chain and sourcing. Malik is also responsible for the commercial and operational execution of Mylan’s growth areas, including the company’s antiretroviral (ARV)/infectious disease, biologics, dermatology, injectables, insulin analog, over-the-counter and respiratory platforms. Malik oversees business development, integration of acquired businesses and information technology with a focus on expanding and enhancing Mylan’s portfolio, product technologies and commercial capabilities. Malik actively promotes the importance and necessity of quality within the company and industry. With a patient-first mentality and a personal philosophy that quality is everyone’s responsibility, Malik has enhanced a long-standing commitment to and obsession with high quality standards that permeate Mylan’s unconventional corporate culture and workforce of about 35,000. Prior to his current role as president, Malik held other leadership positions at Mylan since January 2007, which is when Mylan acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of API and producers of generic finished dose ARVs used to treat HIV/AIDS, primarily for developing markets. Malik was Matrix’s CEO, and during his tenure there, he established the company as a key ARV supplier in developing markets through relationships with Gilead, the Clinton Health Access Initiative (CHAI) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. After Mylan acquired Matrix, Malik focused on novel ARV finished doses, which today form the backbone of Mylan’s leading ARV franchise. Among early contributions at Mylan, Malik partnered with current CEO Heather Bresch to lead integration efforts among Mylan, Matrix and the generics business of Merck KGaA, another 2007 acquisition that catapulted Mylan onto the global stage. Simultaneously, Malik led the creation of a globalized operating platform with a supply chain and manufacturing network that could support the size and complexity of serving all markets around the world. His work also focused on significantly expanding and diversifying the company’s global product portfolio, pipeline and manufacturing footprint. Malik continued to play a key role and further expand the company’s operating footprint through the acquisition of Bioniche Pharma and Agila Specialties, two of the world’s most preeminent makers of injectables products. Most recently, Malik played a pivotal role to acquire and close on the acquisition of Abbott’s Established Products business in non-U.S. developed markets, including Europe, Australia, Japan and Canada. Malik also played a pivotal role in the acquisitions and integrations of Renaissance and Meda which further diversified Mylan’s commercial and operations platform in dermatology and OTC. Malik has approximately 30 years of experience in the global pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started in R&D at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.

Research Interest

global commercial and operational activities sales and marketing pharmaceutical technology